Guardian Therapeutics, LLC is a biotechnology company that researches and develops aptamer-based therapeutics and drug conjugates. The company engineers drug-like aptamers for targeted treatments across multiple therapeutic areas, including hematology, gastroenterology, dermatology, and oncology.
Subscribe to see Guardian Therapeutics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Guardian Therapeutics, LLC is a biotechnology company headquartered in Cambridge, United States. It has raised at least $30M across the 2 funding rounds on record. Its most recent funding round raised $20M in August 2018. Xcout tracks 10 named people at Guardian Therapeutics, LLC, including Jim Gilbert, MD (CEO).
As of 16 November 2026. Source: Xcout Intel.
4 more named people on record for Guardian Therapeutics, LLC, with roles, board committees and tenure — see the full roster →
At least $30M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — | |
| SEC Form D filing | $10M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Guardian Therapeutics, LLC's closest competitors — see the full list of competitors and alternatives →
Aptadir Therapeutics is a biotechnology company based in Milan, Italy, specializing in the development of RNA inhibitor-based therapeutics. The firm focuses on creating novel treatments for intractable cancers and genetic disorders.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
IGF Oncology, LLC develops targeted cancer therapeutics designed to provide higher efficacy and lower side effects compared to traditional chemotherapy drugs. Its lead product, IGF-MTX, combines methotrexate with a targeting protein and has advanced through clinical trials for solid tumors and myelodysplastic syndrome (MDS).
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Aptamino, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on oral antibody delivery utilizing protein design. The privately held, minority- and woman-owned small business has received funding awards from organizations such as DARPA.
Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Guardian Therapeutics, LLC? Suggest a correction · Work at Guardian Therapeutics, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.